NASDAQ:PGEN
Precigen, Inc. Stock News
$1.38
-0.0200 (-1.43%)
At Close: May 17, 2024
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
08:40am, Thursday, 21'st Jul 2022 Benzinga
Gainers
Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.
Direct Digital Ho
This Communication Services Stock Is Trading Higher By Over 82%, Here Are 45 Stocks Moving In Wednesday's Mid-Day Session
04:50pm, Wednesday, 20'th Jul 2022 Benzinga
Gainers
Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares surged 82.2% to $2.6787. Direct Digital Holdings said its supply-side advertising platform, Colossus SSP, reported a 540% year-over-year gr
Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?
11:53am, Wednesday, 20'th Jul 2022 Zacks Investment Research
Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there cou
This Analyst Believes Precigen's Non-Healthcare Divesture Removes Financial Overhang
12:58pm, Wednesday, 06'th Jul 2022
Yesterday, Precigen Inc (NASDAQ: PGEN) agreed to sell its non-healthcare subsidiary to URUS. HC Wainwright says they are encouraged by the divestiture of the company's non-core business and believe
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
09:21am, Wednesday, 06'th Jul 2022 Benzinga
Gainers
Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.
Rubicon Technology, Inc. (NASDAQ: RBCN) shares surged 66.1% to settle at $15.05 on Tuesday after the c
Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session
04:05pm, Tuesday, 05'th Jul 2022 Benzinga
Gainers
Ra Medical Systems, Inc. (NASDAQ: RMED) shares jumped 69.6% to $0.5240 after the company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter.
Rubicon Technology, Inc. (
Why Precigen Shares Are Gaining Today
10:57am, Tuesday, 05'th Jul 2022
Precigen Inc (NASDAQ: PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
10:25pm, Monday, 09'th May 2022 Zacks Investment Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 28.57% and 53.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
07:33pm, Monday, 09'th May 2022
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 28.57% and 53.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
09:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 5.08% and 39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy?
07:00pm, Monday, 02'nd May 2022 Zacks Investment Research
Precigen, Inc. (PGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
12:58pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
10:32am, Tuesday, 05'th Apr 2022
Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.
Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates
02:45pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 7.14% and 14.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Precigen GAAP EPS of -$0.13 beats by $0.01, revenue of $24.22M beats by $1.98M
01:53pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Precigen press release (PGEN): Q4 GAAP EPS of -$0.13 beats by $0.01.Revenue of $24.22M (+25.3% Y/Y) beats by $1.98M.Cash, cash equivalents, and short-term and long-term…